Nelsa Matienzo

Ms. Nelsa Matienzo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2023 in Journal of Lipid Research
Verified
Journal Article
Open access
AMAnastasiya Matveyenko
Anastasiya Matveyenko
NMNelsa Matienzo
Nelsa Matienzo
HGHenry Ginsberg
Henry Ginsberg
RNRenu Nandakumar
Renu Nandakumar
HSHeather Seid
Heather Seid
GRGissette Reyes-Soffer
Gissette Reyes-Soffer
Lipoprotein(a) [Lp(a)] has two main proteins, apoB100 and apo(a). High levels of Lp(a) confer an increased risk for atherosclerotic cardiovascular disease. Most people have two circulating isoforms of apo(a) differing in their molecular mass, determined by the number of Kringle IV Type 2 repeats. Previous studies report a strong inverse relationship between Lp(a) levels and apo(a) isoform sizes. The roles of Lp(a) production and fractional clearance and how ancestry affects this relationship remain incompletely defined. We therefore examined the relationships of apo(a) size with Lp(a) levels and both apo(a) fractional clearance rates (FCR) and production rates (PR) in 32 individuals not on lipid-lowering treatment. We determined plasma Lp(a) levels and apo(a) isoform sizes, and used the relative expression of the two isoforms to calculate a "weighted isoform size" (wIS). Stable isotope studies were performed, using D3-leucine, to determine the apo(a) FCR and PR. As expected, plasma Lp(a) concentrations were inversely correlated with wIS (R2 = 0.27; P = 0.002). The wIS had a modest positive correlation with apo(a) FCR (R2 = 0.10, P = 0.08), and a negative correlation with apo(a) PR (R2 = 0.11; P = 0.06). The relationship between wIS and PR became significant when we controlled for self-reported race and ethnicity (SRRE) (R2 = 0.24, P = 0.03); controlling for SRRE did not affect the relationship between wIS and FCR. Apo(a) wIS plays a role in both FCR and PR; however, adjusting for SRRE strengthens the correlation between wIS and PR, suggesting an effect of ancestry.

1 June 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
GRGissette Reyes-Soffer
Gissette Reyes-Soffer
AMAnastasiya Matveyenko
Anastasiya Matveyenko
JLJames Lignos
James Lignos
NMNelsa Matienzo
Nelsa Matienzo
LBLeinys S Santos Baez
Leinys S Santos Baez
HGHenry Ginsberg
Henry Ginsberg
BACKGROUND: LCAT (lecithin cholesterol acyl transferase) catalyzes the conversion of unesterified, or free cholesterol, to cholesteryl ester, which moves from the surface of HDL (high-density lipoprotein) into the neutral lipid core. As this iterative process continues, nascent lipid-poor HDL is converted to a series of larger, spherical cholesteryl ester–enriched HDL particles that can be cleared by the liver in a process that has been termed reverse cholesterol transport. METHODS: We conducted a randomized, placebocontrolled, crossover study in 5 volunteers with atherosclerotic cardiovascular disease, to examine the effects of an acute increase of recombinant human (rh) LCAT via intravenous administration (300-mg loading dose followed by 150 mg at 48 hours) on the in vivo metabolism of HDL APO (apolipoprotein)A1 and APOA2, and the APOB100-lipoproteins, very low density, intermediate density, and low-density lipoproteins. RESULTS: As expected, recombinant human LCAT treatment significantly increased HDL-cholesterol (34.9 mg/dL; P ≤0.001), and this was mostly due to the increase in cholesteryl ester content (33.0 mg/dL; P =0.014). This change did not affect the fractional clearance or production rates of HDL-APOA1 and HDL-APOA2. There were also no significant changes in the metabolism of APOB100-lipoproteins. CONCLUSIONS: Our results suggest that an acute increase in LCAT activity drives greater flux of cholesteryl ester through the reverse cholesterol transport pathway without significantly altering the clearance and production of the main HDL proteins and without affecting the metabolism of APOB100-lipoproteins. Long-term elevations of LCAT might, therefore, have beneficial effects on total body cholesterol balance and atherogenesis.

27 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NMNelsa Matienzo
Nelsa Matienzo
ZKZoe Kress
Zoe Kress
SSSasha Singh
Sasha Singh
MAMasanori Aikawa
Masanori Aikawa
RSRajesh Kumar Soni
Rajesh Kumar Soni
GRGissette Reyes-Soffer
Gissette Reyes-Soffer
Background: Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). Proteomic studies suggest that Lp(a)-associated proteins mediate inflammation, thrombosis, and vascular calcification, but methodological variability may influence proteome definition. Methods: Lp(a) was immunoprecipitated from human plasma using an apo(a)-specific monoclonal antibody and analyzed by mass spectrometry following either in-gel digestion or automated in-solution proteolysis. Proteins identified by ≥3 unique peptides and consistently detected across all samples by both methods were considered high confidence. Functional enrichment and interaction networks were assessed using STRING. Results: In-solution proteolysis identified 92 proteins and in-gel digestion identified 55 proteins, with 34 proteins shared between methods. These high-confidence proteins were enriched for pathways involved in lipoprotein remodeling, coagulation regulation, vesicle-mediated transport, lipid binding, and extracellular matrix organization, providing biological insight into mechanisms linking Lp(a) to inflammation, thrombosis, and calcification. Conclusions: Proteome composition of Lp(a) is method-dependent; however, a rigorously defined core proteome of 34 proteins was consistently identified across analytical approaches, highlighting biologically relevant pathways that may underlie Lp(a)-mediated ASCVD risk.

9 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
TTTiffany Thomas
Tiffany Thomas
AMAnastasiya Matveyenko
Anastasiya Matveyenko
NMNelsa Matienzo
Nelsa Matienzo
MKMichael Kissner
Michael Kissner
SMSantica Marcovina
Santica Marcovina
GRGissette Reyes-Soffer
Gissette Reyes-Soffer
Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease composed of apolipoprotein(a) [APO(a)] covalently linked to apolipoprotein B100 (APOB). Although plasma Lp(a) concentrations are largely genetically determined, the mechanisms governing Lp(a) metabolism after particle assembly remain poorly understood. We performed a cross sectional, observational study to define the Lp(a) proteome and determine the metabolic behavior of APO(a) and APOB within circulating Lp(a) particles using integrated proteomic, kinetic, and imaging approaches. Sixteen healthy adults underwent stable isotope tracer studies with ²H₃-L-leucine and ²H₅-glycerol. Lp(a) particles were isolated by APO(a)-specific immunoprecipitation for high-resolution liquid chromatography–mass spectrometry and kinetic analyses, and extracellular vesicles (EVs) were characterized by imaging flow cytometry and super-resolution microscopy. Proteomic analysis identified 92 proteins associated with immuno-isolated Lp(a), enriched in pathways related to immunity, coagulation, and atherogenesis. Lp(a)-APO(a) exhibited a mean fractional clearance rate of 0.04 pools/day, whereas Lp(a)-APOB cleared approximately sevenfold faster (0.25 pools/day), independent of plasma Lp(a) concentration or APO(a) isoform size. Both APO(a) and APOB were detected on circulating EVs, suggesting that EVs may contribute to post-secretory Lp(a) particle remodeling. These integrated human studies demonstrate marked discordance between APO(a) and APOB turnover within circulating Lp(a) particles, challenging the prevailing assumption that both apolipoproteins behave as a single metabolic unit after Lp(a) assembly and supporting a revised model of human Lp(a) metabolism.

7 June 2026 in bioRxiv
Verified
Preprint
Open access
ABAlexander C. Bashore
Alexander C. Bashore
BHBenedek Halmos
Benedek Halmos
AGAnouk G. Groenen
Anouk G. Groenen
AMAnastasiya Matveyenko
Anastasiya Matveyenko
NMNelsa Matienzo
Nelsa Matienzo
GRGissette Reyes-Soffer
Gissette Reyes-Soffer
Background: Lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular disease (CVD), with plasma concentrations higher in Black individuals than in White individuals. Published findings support a model in which high Lp(a), in part through oxidized phospholipid (oxPL)-mediated signaling, promotes a pro-inflammatory monocyte phenotype that may contribute to arterial wall inflammation and the development of CVD. Here, we examined the relationship between Lp(a) concentrations and isoform size and the distribution of circulating monocyte populations in Black and White individuals using single-cell RNA sequencing (scRNA-seq) data. Methods: Using standardized assays, we measured plasma Lp(a) levels, isoform size, inflammatory markers, and oxidized phospholipids in stored plasma samples from our previously published cohort of 128 participants. After excluding smokers and individuals with type II diabetes, a total of 34 participants (20 Black participants, 14 White participants) were included in analyses. Participants were further stratified by plasma Lp(a) levels into normal Lp(a) [median 12.6 nmol/L, with 15 individuals (8 Black participants) and high Lp(a) (median 159 nmol/L, with 19 individuals (12 Black partcipants)]. Multivariable linear regression was used to assess the association between plasma Lp(a) levels, Lp(a)-oxPL, and the proportion of monocyte subsets. Across all participants, scRNA-seq data identified six classical monocyte subsets, one non-classical monocyte subset, one MHCII hi monocyte subset, and one interferon (IFN)-responsive monocyte subset. Results: The distribution of monocyte subsets was similar in individuals with normal versus high Lp(a) levels. Despite the small study cohort, self resported race modified the assocation between plasma Lp(a) levels and the proportion of non-classical monocytes ( P = 0.032), which was inversely associated in White participants ( P = 0.028), but not in Black partcipatns ( P = 0.470). OxPL bound to APO(a) showed a positive correlation with plasma Lp(a) levels (R 2 = 0.84; P = 3.3×10 −14 ), and non-classical monocytes ( P Whites = 0.027; P Blacks = 0.275; P Interaction = 0.014). Race also modified the association between plasma Lp(a) levels and the proportion of classical 2 monocytes ( P = 0.027). Conclusions: These results underscore the importance of self reported race when analysing studies on Lp(a), monocytes and, cardiovascular related monocyte immune functions.